Our Company

ADC Therapeutics is a clinical-stage oncology biotechnology company leading the development and commercialization of next-generation antibody-drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine dimer technology.

Learn More ButtonLearn More Button

ADC Therapeutics Corporate Video

Our Pipeline

Proprietary PBD-based technology is the foundation for a diversified pipeline of ADCs in the treatment of hematological cancers and solid tumors.

View Pipeline ButtonPipeline View Button

Our Clinical Trials

Our PBD-based ADCs are advancing through clinical trials in multiple hematological and solid tumor indications.

Lead candidate Loncastuximab Tesirine (Lonca) is being evaluated in a pivotal phase 2 study in patients with relapsed or refractory DLBCL and ADCT intends to commence a phase 3 randomized study of Lonca in combination with rituximab versus immunochemotherapy.

Find Out More ButtonFind Out More Button


July 17, 2020

ADC Therapeutics Announces First Patient Dosed in Pivotal Phase 2 Portion of LOTIS 3 Clinical Trial of Loncastuximab Tesirine (Lonca) in Combination With Ibrutinib


July 6, 2020

ADC Therapeutics Announces U.S. Food and Drug Administration Has Lifted Partial Clinical Hold on Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine


June 12, 2020

ADC Therapeutics Announces Maturing Data from Pivotal Phase 2 Clinical Trial and Phase 1/2 Combination Clinical Trial of Loncastuximab Tesirine (Lonca) in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma